

CURRICULUM VITAE FOR
Case Western Reserve University School of Medicine

Date: 6/1/18

Personal Information

Name: Gripshover, Barbara Marie

Education:

Miami University, Oxford, OH
BS Magna cum laude, Botany, BA Chemistry
1980

Purdue University, W. Lafayette, IN
MS Cell Biology
1983

Vanderbilt University Medical School, Nashville TN
MD
1987

Postgraduate Training:

University Hospitals of Cleveland, Cleveland, Ohio
Internal Medicine Resident
1987-90

University Hospitals of Cleveland, Cleveland, Ohio
Chief Medical Resident
1990-91

University Hospitals of Cleveland, Cleveland, Ohio
Fellow, Division of Infectious Diseases
1991-93

Johnson and Johnson/UCLA Health Care Executive Program
2006

Contact Information:

Office Address: 2016 Cornell Road, Room 405
Cleveland, OH 44106-5083
Office Phone: 216-844-5876
Beeper: 216-207-7244 #30646
Email: bxg9@case.edu
Fax: 216-844-1632

Professional Appointments

Medical Director, John T. Carey Special Immunology Unit
University Hospitals of Cleveland, Department of Medicine
1997-present

Infectious Diseases and Internal Medicine Attending Physician
University Hospitals of Cleveland, Department of Medicine
1993-present

Associate Medical Director, John T. Carey Special Immunology Unit
Co-medical Director, Continuing Medical Education
University Hospitals of Cleveland, Department of Medicine
1996-97

Medical Director, HIV Inpatient Care
University Hospitals of Cleveland, Department of Medicine
1994-96

Academic Appointments

Associate Professor of Medicine, Division of Infectious Diseases and HIV Medicine
Case Western Reserve University School of Medicine, Department of Medicine
2001-present

Assistant Professor of Medicine, Division of Infectious Diseases
Case Western Reserve University School of Medicine, Department of Medicine
1993-2001

Certification and Licensure

National Board of Medical Examiners
Part I 1985; Part II 1986; Part III 1988

Ohio Medical Board Medical License
1990
35-060776
11/2/1990-1/1/2019

American Board of Internal Medicine
1990; Recertified, ABIM 2004, 2014

#133102
1990-2000; 2004-2024

ABIM, Subspecialty of Infectious Diseases
1994; Recertified, ABIM Subspecialty of Infectious Diseases 2004, 2014
#133102
1994-2024

Honors and Awards

Faculty Development Award for Subspecialty Clinical Teaching, CWRU Department of Medicine 1996, 1997

Best Doctors, Best Doctors Inc
2001-2, 2003-4, 2005-6, 2007-8, 2009-2010, 2011-12, 2013-4, 2015-6, 2017-8

Master Clinician Educator Award, CWRU/UHCMC/VA Department of Medicine 2018

Membership in Professional Societies

Infectious Diseases Society of America (IDSA) 1993-present
Fellow, IDSA 2009

HIV Medicine Association of IDSA (HIVMA) 2000-present

International AIDS Society 1998-present

Professional Services

Reviewer:

International AIDS Society International AIDS Conference and IAS Pathogenesis
Conference abstract reviewer 2012, 2013, 2014, 2015, 2016, 2017, 2018

Clinical Infectious Diseases *ad hoc*

Advisory Groups:

Ohio Department of Health AIDS Drug Assistance Program/Ryan White Part B Advisory
Committee, 1996-present

Ryan White Title I/Part A Planning Council for Northeast Ohio, 1997-ongoing

Ryan White Part A Planning Council Quality Subcommittee 2012-ongoing

Clinton HIV/AIDS Initiative, Clinical Mentor, Bahamas National AIDS Program 2008

Committee Service

National:

2005-7 HIVMA Ryan White Reauthorization Working Group

2006-present HIVMA Ryan White Medical Provider Coalition Steering Committee
2012-2014 Co-chair

2011-2012 HRSA National Quality Center in+Care Campaign Technical Advisory Group

2012 IDSA Maintenance of Certification (MOC) Development Panel for HIV module

9/6/2017 HRSA Technical Expert Panel on Preliminary Proposed Methodology for Ryan White HIV/AIDS Program Services Provider Benchmarking

5/31/2016-11/30/2019 FDA Antimicrobial Drug Advisory Committee Standing Member

Hospital (University Hospitals Cleveland Medical Center):

1993-1995 University Hospitals Infection Control Committee

1994-1996 TB Collaborative Carepath,

1994-2012 Department of Medicine Intern Selection Committee

1995-2001 Anti-infective Utilization Subcommittee of the Pharmacy and Therapeutics Committee

1997-1998 Department of Medicine Chair Search Committee

2002-2006 Department of Medicine Promotions and Tenure committee

2007-2012 Department of Medicine Institutional Review Board committee

University:

2013-14 Chair, DSMB for Dr. Grace McComsey's NIH-funded Randomized placebo-controlled trial of rosuvastatin in HIV-infected subjects to modulate cardiovascular risk and inflammation

2013-16 DSMB member for Dr. Jacquelyn Slomka's RO1: Randomized Trial of an HIV Navigation Program for Early Palliative Care

2015-2017 DSMB member for Dr. Allison Webel's American Heart Association funded study: "A Randomized Clinical Trial of SystemCHANGE to improve Exercise, Diet, and Health in HIV- Infected Adults" and the accompanying sub-study protocol "The Effect of SystemCHANGE on Cognitive Processing and Cardiac Health in HIV+ Adult"

2016-ongoing Chair, DSMB for Dr. Grace McComsey's NIH-funded R21-AT009153 Phase1 Pilot study of zinc supplementation in HIV-infected subjects

2018-ongoing Chair, DSMB for Dr. Irina Pikuleva's Alzheimer's Drug Development Foundation sponsored Proof-of -concept Clinical Research Study of Efavirenz in Patients with Alzheimer's Disease

Teaching Activities

Course lectures/small groups:

3rd year internal/family medicine UH/VA clerkship students "HIV for Primary Care Providers" lecture 4 times/year 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017

Block 5 Second year medical students "Immunocompromised Host Cases" 2 hours 10/16, 10/17

EPBI 494 "HIV Prevention" 1 hour lecture 2012, 2013

Second year medical students MOI II "Sexually Transmitted Diseases" 1 hour 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006

INTH 801 "Antifungal Therapy" and "Sexually Transmitted Diseases" International Health graduate student course 1 hour each 1999, 2000, 2001, 2002, 2003

IMMU 2002 "GI Complications" Case Studies in HIV 1st and 2nd year medical students 2 hours 2002, 2003

DAB Committee Second year medical students "Antiviral Therapy" 8 hours 1999, 2000

EPBI 494 "Sexually Transmitted Diseases" 1 hour lecture 1999, 2000

IMMU 5003 "Meningitis" Case Studies in Infectious Disease 2 hours 1999, 2000

MU 6002 "Chronic Meningitis" Major ID Syndromes 2 hours 1999

Presentations:

Local/Regional:

“HIV: An epidemic in evolution” Oberlin College, Oberlin OH 11/14/17

What happens at the PrEP provider” Cleveland community HIV testing agencies 5/19/17

“HIV Pre-exposure Prophylaxis” UHCMC OB/gyn Grand Rounds 6/15/16

“HIV: an epidemic in evolution” World AIDS Day conference Louis Stokes Cleveland VA 12/7/15

"What happens in the PrEP clinic" AIDS Funding Collaborative PrEP conference for Cleveland area community HIV testing agencies 6/12/15

“HIV Pre-exposure Prophylaxis" Cleveland Metrohealth Medical Center ID clinic retreat 4/30/15

“Pre-exposure Prophylaxis” Cleveland Clinic HIV Grand Rounds 9/5/14

“HIV PEP and PrEP” UH Emergency Department noon conference, residents and faculty 7/24/14

“Update on HIV Prevention” World AIDS Day Community forum CWRU 12/2/13

“HIV 101 Panel” ODH sponsored “Ohio Talks HIV” conference for RNs and LSWs CSU 5/22/13

“Linkage and Retention-the Key to the End of AIDS?” Northeast Ohio HIV Providers Post CROI Update 3/28/2013

“New Drugs in the Pipeline 2012” ODH Ryan White Part B Advisory Committee, Columbus OH 9/13/12

“HIV Domestic Policy” CWRU AMSA 12/2/11

“Update on HIV Prevention” World AIDS Day Community forum CWRU 11/30/11

“CROI 2010 Update” University of Toledo Infectious Disease Department 3/12/10

“Importance of CD4 and viral load monitoring” Cleveland Ryan White Part A Planning Council 9/10/09

“New Antiretroviral Therapies” AIDS Taskforce of Greater Cleveland 4/07

“HIV Update” UHCMC Ophthalmology Grand Rounds 12/5/07

“CROI Update” HIV Primary care physicians Cleveland 2/24/06

“CROI Update” University of Toledo Infectious Disease division 3/31/06

“Post CROI Update” Medical College of Toledo Infectious Disease division 3/10/04,
3/05

“CROI Update” Free Clinic of Cleveland HIV Providers 5/21/04

“HIV Care and its Cost” Cleveland Ryan White Title I Planning Council 9/03, 9/15/04

“HIV Resistance” City wide ID fellows, Cleveland 11/18/04

“HIV in Minorities” ACTU/SIU Community Forum 9/03

“Update from 9th CROI” Northeast Ohio AIDS Physicians 3/02

“Update from XIVth World AIDS Conference” Northeast Ohio AIDS Physicians 8/02

“HIV in Minorities” Douglas Satcher lecture series UH/CWRU 11/20/01

“Update in HIV” Lakewood Hospital Grand Rounds 2/14/01

“IAS Update” University of Toledo Infectious Disease division 10/17/01; Northeast Ohio
AIDS physicians 8/7/01; Free Clinic of Cleveland 9/25/01

“New Concepts from the World AIDS Conference” Northeast Ohio AIDS Physicians
8/2/00

“Structured Treatment Interruptions” NE Ohio ID Roundtable 9/27/00

“HIV Testing in the Emergency Department” UH Emergency Department Conference
10/10/00

“HIV Update” NE Ohio AIDS Education and Training and Education conference, Medina
Hospital 10/12/00

National/International:

"HIV Pre-exposure Prophylaxis" Kentucky AIDS Education and Training Center Annual
Conference, Lexington, KY 4/18/15

“Initiating Antiretroviral Therapy” and “Antiretroviral Drug Side Effects” and “ From
North to South and South to North; from America and beyond” Eastern Cape Regional
Training Centre, Integrating HIV and Mental Health Care Workshop, Walter Sisulu
University, East London, South Africa 10/29/12-10/31/12

“Tracking Mortality in the John T. Carey Special Immunology Unit” HIVQUAL-US Clinical Advisory Committee, Health Service and Patient Outcomes subcommittee webinar 1/23/12

“Cardiovascular Complications of HIV” National Conference on HIV 2009, Hyderabad, India 8/8/09

“HIV Resistance and New Drugs” Hospital Roosevelt, Guatemala City, Guatemala 4/6/09

“The physician-patient relationship” National Association for Persons living with AIDS National Conference 8/24/07

“New Antiretroviral Drugs and Multidrug Resistant HIV” Coordenacao Estadual de DST/AIDS, Secretariade Saude do Estado do Espirito Santo, Vitoria, Brazil 7/29/05

Mentees:

Clinical in weekly HIV clinic:

Infectious Disease fellows:

Nadim El-Chakhtoura 2014-16, now Wade Park VA Cleveland hospitalist
Sudha Nagalingam 2012-15, now El Rio Health Center, Tucson HIV clinic
Myreen Tomas 2011-14, now Assistant Professor, Infectious Disease, CWRU (UH)
Elizabeth Harauscz 2012-2014, now U.S. Military HIV Research Program
Jessica Jones 2009-11, now Methodist Physicians Clinic, Infectious Disease, Omaha NE
Jessica Fairley 2007-10, now Assistant Professor, Infectious Disease, Emory
Laila Woc-Coburn 2006-09, now Associate Professor, Infectious Disease, Baylor
Corrilyn Hileman 2008-09, now Assistant Professor, Infectious Disease, CWRU (Metro)
Wafa Al-Nassir 2005-07, now National Guard Health Affairs, Infectious Disease, Saudi Arabia
Lucileia Teixeira-Johnson 2004-06, now Clinical Assistant Professor, Infectious Disease CWRU (CCF)
Matt Meyer 2003-05, private Infectious Disease practice
Eddie Jones 1999 -01, now Assistant Professor of Infectious Disease, Boston University

Family medicine fellow:

Todd Wagner 7/11-6/12, now Medical Director, Care Alliance, Cleveland

Internal medicine residents:

Nadim El-Chakhtoura 8/12-6/14, now Wade Park VA Cleveland hospitalist
Katherine Mullin 7/12-6/13, now ID staff Cleveland Clinic Foundation
John Winters 8/11-6/13, now New York City Department of Health and Mental Hygiene
Trevor Crowell 8/09-6/11, now U.S. Military HIV Research Program
Allison George Agwu 2002-3, now Associate Professor of Pediatric and Adult Infectious Disease, John Hopkins

MTSP Clinical Tutorial MEDS 4010M:

Claire Mazahery 11/16-8/17

Ryan Stultz 9/13-5/14

MPH Capstone Committee member:

Nora Colburn 2010-13 now with ID Consultants, Cleveland

PhD Committee member:

Yanina Natanzon PhD graduate student in Epi and Biostats, defense 9/28/2015

Gold Foundation Summer Service Fellowship mentor:

Karen Lewicki, medical student 2012

Cleveland Clinic Lerner School of Medicine, MD thesis committee chair (currently)

Joshua Niforatos, medical student graduating 2019

Additional Teaching Activities: (lectures to trainees, clinical teaching rotations)

"Approach to the HIV patient in the hospital or emergency room" New ID fellows 8/2009, 8/10, 8/11, 8/12, 8/13, 8/14, 8/15, 8/16, 8/17

"Acute HIV: DDX, diagnosis and management" Infectious Disease fellows didactics conference 5/17/17

"Meningitis" Infectious Disease fellows didactics conference 3/13/17

"HIV Pre-exposure Prophylaxis" Infectious Disease fellows didactics conference 1/12/15, 3/1/17

"Klebsiella Endophthalmitis" UHCCM Dept of Medicine, M and M conference 4/22/16

"HIV Board Review" UH internal medicine residents 6/02, 6/03, 2/24/04, 6/7/09, 6/10/15

"Failure to Thrive in an HIV Patient" UHCCM Dept of Medicine, M and M conference 8/9/14

"Acute HIV infection, PEP and PrEP" Infectious Disease fellows didactics conference 12/12/11, 2/24/14

"Acute HIV infection" UHCCM Dept of Medicine, M and M conference 8/8/13

"HIV Prevention including PrEP" Infectious Disease fellows didactics conference 11/12/12

"Fever of Unknown Origin in HIV infected persons" Dept of Medicine, M and M conference 8/5/11

"Progressive Multifocal Leukoencephalopathy" Dept of Medicine, M and M conference 4/8/11

“CNS infections in Immunocompromised Host” Dept of Medicine, M and M conference 2/11/11

“HIV Cases” Infectious Disease fellows 5/21/09, 5/7/10, 11/18/10

“Diarrhea in HIV” Dept of Medicine, M and M conference 6/25/10

“Meningitis” UH Critical Care Fellows conference 3/2/09, 3/1/10

“HIV Drug Resistance” Infectious Disease fellows didactics conference 6/21/04, 3/27/06, 9/17/09

“Parvovirus” Dept of Medicine, M and M conference 5/8/09

“Aseptic and Chronic Meningitis” Infectious Disease fellows didactics conference 12/02, 3/9/09

“HIV Emergencies” Infectious Disease fellows didactics conference 2007, 2008

“Chronic Meningitis” Infectious Disease fellows didactics conference 2000, 2003, 2007

“Approach to the Newly Diagnosed HIV Patient” Internal medicine didactics conference 9/00, 8/02

“Primary HIV Infection” Internal medicine didactics conference 7/20/01

“Meningitis” Internal medicine didactics conference 12/7/01

“Needlestick Protocol” Dept of Medicine, M and M conference 9/21/00

“Sexually Transmitted Diseases” Internal Medicine and Pediatric residents UH 11/8/00

Research Support

Current (as Principal Investigator):

1. Ryan White Part A* (Gripshover, site PI) 3/01/18-02/28/19 15%
HRSA/Cuyahoga County subcontract \$421,686 (partial award due to delay in federal budget approval)
Clinical care of underserved HIV infected persons including physician, nursing, labs, dental, nutrition, medical case management and mental health counseling.
2. 2 H76HA00608-18-00 (Gripshover) 4/1/18-3/31/21 35%
Ryan White Part C* \$507,823 annual
HRSA

Clinical care of underserved HIV infected persons including physician, nursing, medical and surgical specialty care, pharmacist, financial counselor, and clinical quality management

3. 1 H12HA24823-06-00 (Gripshover) 8/1/17-7/31/20 20%
Ryan White Part D* \$357,224 annual
HRSA

Clinical care of underserved HIV infected women and youth including physician, Ob/gyn, nursing, medical and surgical specialty care, youth case manager, and clinical quality management.

* The federal Ryan White HIV/AIDS program provides medical and support services to underserved persons living with HIV. It is administered by the Health Resources Services Administration (HRSA) and composed of multiple parts. Part A funds go to health departments in urban areas most severely affected with HIV, and then are subcontracted to local HIV providers in an RFP process. The greater Cleveland Part A Transitional Grant Area (TGA) award goes to Cuyahoga County Board of Health. Part B funds go to state health departments to fund AIDS Drug Assistance Programs and medical and support services as the state chooses. Part C funds are awarded from HRSA to community-based HIV clinics (including those in academic medical centers) via competitive funding opportunities to be used to provide comprehensive HIV care services. Part D funds are awarded from HRSA to clinics via competitive funding opportunities to provide comprehensive HIV care services specifically for women, youth and children.

Current (as Co-Investigator):

1. 1 U01 AI069501-01 (Lederman) 12/10/13-11/30/20 3%
NIH-NIAID \$1,655,783 annual
Adult AIDS Clinical Trials Unit
HIV/AIDS clinical trials development and implementation

Past (as Principal Investigator):

1. Agouron Pharmaceuticals (Gripshover) 3/1/96-2/28/97
AG1343-506 \$103,350
A Phase III randomized, double blind, placebo-controlled study of Viracept (nelfinavir) in combination with stavudine versus stavudine alone in HIV positive patients
2. Merck (Gripshover) 7/1/96-6/30/97
MK-639 Protocol 037 \$84,240
A Multiclinic, double-blinded, randomized, one year study to compare the safety and efficacy of MK-639 (indinavir), 800mg q8h administered concomitantly with stavudine, dosed by body weight, to that of MK 639 alone and stavudine alone.
3. Ryan White Title I/Part A (Gripshover, site PI)

HRSA / Cuyahoga County subcontract

Clinical care of HIV infected underserved persons

03/01/97-02/28/98	\$101,195	5 %
03/01/98-02/28/99	\$181,814	5%
03/01/99-02/28/00	\$201,257	5%
03/01/00-02/28/01	\$227,925	5%
03/01/01-02/28/02	\$283,289	5%
03/01/02-02/28/03	\$285,773	6%
03/01/03-02/29/04	\$312,380	10%
03/01/04-02/28/05	\$360,000	15%
03/01/05-02/28/06	\$418,089	15%
03/01/06-02/28/07	\$377,795	15%
03/01/07-01/28/08	\$418,353	15%
03/01/08-02/28/09	\$466,000	15%
03/01/09-02/28/10	\$488,462	10%
03/01/10-02/28/11	\$403,269	5%
03/01/11-02/29/12	\$533,039	5%
03/01/12-02/28/13	\$554,754	20%
03/01/13-02/28/14	\$586,102	25%
03/01/14-02/28/15	\$653,968	15%
03/01/15-02/28/16	\$817,301	10%
03/01/16-02/28/17	\$1,023,226	10%
03/01/17-02/28/18	\$1,106,512	15%

4. Ryan White Title II/Part B* (Gripshover)

HRSA/ Ohio Dept of Health

Support for medical case management of HIV infected underserved persons

04/01/02-03/31/03	\$77,166	0%
04/01/03-03/31/04	\$101,249	0%
04/01/04-03/31/05	\$106,000	0%
04/01/05-03/31/06	\$106,000	0%
04/01/06-03/31/07	\$108,000	0%
04/01/07-03/31/08	\$122,000	0%
04/01/08-03/31/09	\$168,494	0%
04/01/09-03/31/10	\$125,494	0%
04/01/10-03/31/11	\$125,494	0%

5. H76 HA 00608-02-02 (Gripshover)

9/30/00-3/31/04

55%

Ryan White Title III (Part C)

\$1,722,807 total

HRSA

Clinical care of underserved HIV infected persons

6. 2 H76HA00608-04-00 (Gripshover)

4/1/04-3/31/07

55%

Ryan White Title III (Part C)

\$1,606,000 total

HRSA

Clinical care of underserved HIV infected persons

- | | | | |
|-----|---|--|------|
| 7. | 2 H76HA00608-07-00 (Gripshover)
Ryan White Part C (Title III)
HRSA
Clinical care of underserved HIV infected persons | 4/1/07-3/31/12

\$491,000 annual | 45% |
| 8. | 2 H76HA00608-12-00 (Gripshover)
Ryan White Part C
HRSA
Clinical care of underserved HIV infected persons | 4/1/12-3/31/15

\$491,400 annual | 30% |
| 9. | 2 H76HA00608-15-00 (Gripshover)
Ryan White Part C
HRSA
Clinical care of underserved HIV infected persons | 4/1/15-3/31/18

\$466,830 annual | 35% |
| 10. | 1 H12HA2483-01-00 (Gripshover)
Ryan White Part D
HRSA
Clinical care of underserved HIV infected women and youth | 8/1/12-7/31/15

\$350,000 annual | 20% |
| 11. | 1 H12HA24823-01-11 (Gripshover)
Ryan White Part D
HRSA
Clinical care of underserved HIV infected women and youth | 8/1/15-7/31/17

\$305,550 annual | 20% |
| 12. | Gilead Sciences (Gripshover)
PMPA Pro-drug
Multicenter Phase II trial of tenofovir in treatment experienced HIV infected persons with virologic failure on current regimen | 8/15/98-8/15/00
\$73,331 | |
| 13. | Glaxo Wellcome (Gripshover)
Amprenavir ESS40006
Multicenter Phase II trial of ritonavir boosted amprenavir in treatment experienced HIV infected persons with virologic failure on current regimen | 5/15/00-4/22/01
\$34,114 | |
| 14. | AIDS Funding Collaborative (Gripshover)
United Way
Local investigator initiated grant to institute HIV testing in our emergency room to increase outreach to African Americans at risk for HIV infection. | 09/01/00-08/31/01
\$33,000 | 2.5% |
| 15. | VAX004 (Gripshover)
VaxGen
Multicenter study of an HIV gp120 vaccine in HIV negative men at high risk of HIV | 03/01/99-02/28/02
\$100,371 | 5% |

infection.

- | | | |
|---|-------------------|----|
| 16. GRU0018FGS-I-01 (Gripshover, site PI) | 12/1/99-08/31/03 | 5% |
| NIH | \$239,003 | |
| FRAM Study | | |
| Multi-center cross sectional multi-site study of fat redistribution and metabolism in persons with HIV infection and age matched controls (Grunfeld UCSF/VA, study PI)\ | | |
| 17. Special Projects of National Significance (Gripshover). | 9/01/05-2/28/07 | 5% |
| 1 H97HA05563-01-00 | \$75,000 | |
| HRSA | | |
| Implement OPTIONS program of incorporating teaching HIV prevention behaviors to HIV infected persons as part of routine HIV medical care | | |
| 18. Boehringer-Ingelheim (Gripshover) | 03/01/03-09/01/07 | |
| BI1181.12 | \$48,270 | |
| Multicenter trial of tipranivir/ritonavir vs other boosted protease inhibitors in multidrug resistant HIV infected persons | | |
| 19. TDM (Gripshover, site PI) | 7/01/03-6/30/07 | 5% |
| 1RO1 DA015024-01A2 NIH/NIDA | \$139,600 | |
| Multicenter study of therapeutic drug monitoring to evaluate drug interactions in HIV infected persons on antiretroviral therapy (Morse SUNY Buffalo, study PI). | | |
| 20. FRAM 2 (Gripshover, site PI) | 1/1/04-04/08/08 | 5% |
| ROI HL074814-04 | \$295,328 total | |
| NIH National Heart, Lung and Blood Institute | | |
| Cross sectional multi-site study of fat redistribution and metabolism in persons with HIV infection and age matched controls | | |

Past (as Co-Investigator)

- | | | |
|---|--------------------|----|
| 1. AI25879 (Lederman) | 2/1/96-12/31/99 | 5% |
| NIH-NIAID | \$1,168,731 | |
| Adult AIDS Clinical Trials Group | | |
| Multicenter program of clinical trials studying treatment of HIV infection and its complications. | | |
| 2. AI25879 (Lederman) | 01/01/00-11/30/06 | 5% |
| NIH-NIAID | \$1,303,776 annual | |
| Adult AIDS Clinical Trials Unit | | |
| HIV/AIDS clinical trials development and implementation | | |

Bibliography

Peer Reviewed Articles

1. Buckhout TJ, **Gripshover BM**, Morre DJ: Endoplasmic reticulum formation during germination of wheat seeds: a quantitative electron microscope study. *Plant Physiology* 68:1319-22, 1981.
2. Moore DJ, **Gripshover BM**, Boss W, Tuite P: Membrane cell-free systems for probing plant growth mechanisms. *Annual Proceedings of the Phytochemical Society of Europe* 24:247-65, 1984.
3. Moore DJ, **Gripshover BM**, Monroe A, Morre J: Phosphatidyl inositol turnover in isolated soybean (*Glycine max*) membranes stimulated by the synthetic growth hormone 2,4-D, *J Biol Chem* 259:15364-8, 1984.
4. **Gripshover BM**, Moore DJ, Boss W: Fractionation of suspension cultures of wild carrot (*Daucus carota*) and kinetics of membrane labeling. *Protoplasma* 123:213-20, 1984.
5. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, **Gripshover BM**, Mbanefo C, Phinney M, Rahman M, Salata RA, Weigel K and Kalayjian RC: Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. *Am J Med* 101:41-48, 1996.
6. Valdez H, **Gripshover BM**, Stover MD and Salata RA: *Mycobacterium avium* complex osteomyelitis in HIV-infected patients: Case report and review. *Infectious Diseases in Clinical Practice* 1016(5):351-353, 1997.
7. Valdez H, **Gripshover BM**, Salata RA and Lederman MM: Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy. *AIDS* 12(5):538, 1998.
8. **Gripshover BM**, Valdez H, Salata RA and Lederman MM: Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors. *AIDS* 12(18):2513-2514, 1998.
9. Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, and **Gripshover BM**. HIV-1 protease inhibitors in a clinical practice: predictors of virologic outcome. *Archives of Internal Medicine* 159:1771-1776, 1999.
10. Valdez H, Metcalf JA, **Gripshover BM**, Jacobson M, Mitsuyasu R, Lederman MM. Effect of Interleukin-2 (IL-2) Therapy on Plasma HCV-RNA Levels in HIV/HCV Co-Infected Patients. *AIDS* 15(5): 661-2, 2001.
11. Valdez H, Chowdhury T, Assad R, Woolley I, Davis T, Davidson R, Beinker N, **Gripshover**

BM, Salata RA, McComsey G, Weissman SB, Lederman MM. The Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths from 1995-1999. *Clin Infect Dis* 2001 May 15;32 (10):1487-93.

12. Lange CG, **Gripshover BM**, Valdez H, Lederman MM. Manifestation of hyper-IgE syndrome in advanced HIV-1 infection. *MedKlin* 2002 Jan 15;97(1):34-9.

13. Southwell H, Valdez H, Lederman M, **Gripshover B**. Use of Alternative therapies among HIV-infected patients at an urban tertiary care center. *J AIDS*. 2002 31 (1):119-20.

14. McComsey G, Southwell H, **Gripshover B**, Salata R, and Valdez H. Effect of Antioxidants on Glucose Metabolism and Plasma Lipids in HIV-infected Subjects with Lipoatrophy. *J AIDS* 2003; 33:605-607.

15. Shafer RW, Smeaton LM, Robbins GK, DeGruttola V, Snyder SW, D/Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, **Gripshover BM**, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med* 2003; 349(24):2304-15.

16. Loupa CV, Lederman MM, Valdez H, Salata RA, McComsey GA, **Gripshover B**, Fulton S, Lisgaris MV, Kucia M, Asaad R, Cline J, Rodriguez B. New Entrants to HIV Care Are Presenting Only at Marginally Earlier Stages of Disease but May Increasingly Represent Groups Perceived at Lower Risk. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2005 Apr-Jun; 4(2):47-51.

17. Bacchetti P, **Gripshover B**, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat Distribution in Men with HIV Infection. *J AIDS* 2005;40:121-131.

18. Loupa CV, Rodriguez B, McComsey G, **Gripshover B**, Salata RA, Valdez H, Lisgaris ML, Fulton SA, and Lederman MM. Gender Differences in Human Immunodeficiency Virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. *Clin Microbiol Infect* 2006; 12: 389-391.

19. **Gripshover BM**, Ribaldo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, and Kuritzkes DR. Amdoxovir vs Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1 Infected Subjects Failing Current Therapy (AACTG A5118). *Antiviral Therapy* 2006; 11: 619- 23.

20. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat Distribution in Women with HIV Infection. *J Acquir Immue Defic Syndr*. 2006; 42(5): 562-71.

21. Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, **Gripshover BM**, Venuto CS, Slish JC, Difrancesco R, Forrest A, Morse GD. Multidrug resistance 1 polymorphisms and

trough concentrations of atazanavir and lopinavir in patients with HIV. *Pharmacogenomics*. 2007; 8(3):227-235.

22. Keil K, Hochreitter J, Difrancesco R, Zingman BS, Reichman RC, Fischl MA, **Gripshover B**, Morse GD. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. *Ther Drug Monit*. 2007 Feb; 29 (1):103-9.

23. Tien PC, Bacchetti P, **Gripshover B**, Overton ET, Rimland D, Kotler D; and the Fat Redistribution and Metabolic Change in HIV Infection Study Investigators. Association Between Hepatitis C Virus Coinfection and Regional Adipose Tissue Volume in HIV-infected Men and Women. *J Acquir Immune Defic Syndr*. 2007; 45(1):60-5.

24. Difrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, **Gripshover B**, Morse GD. Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. *J Pharm Biomed Anal* 2007; 44(1):188-95.

25. Hu Z, Hatano H, Hammond SP, Smith D, Wild M, Gupta S, Whitcomb J, Kalayjian RC, **Gripshover B**, Kuritzkes DR. Virologic Characterization of HIV Type 1 With a Codon 70 Deletion in Reverse Transcriptase. *J Acquir Immune Defic Syndr* 2007; 45(5):494-500.

26. Sligh J, Ma Q, Zingman BS, Reichman RC, Fischl MA, **Gripshover B**, Forrest A, Brazeau D, Boston NS, Catanzaro L, Difrancesco R, Morse GD. Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV- Infected Patients During Therapeutic Drug Monitoring. *Ther Drug Monit*. 2007; 29(5): 560- 65.

27. Higgins N, Zingman BS, Sligh J, Reichman RC, Fischl MA, **Gripshover B**, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD. Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. *Am J Addict*. 2007 Nov-Dec;16(6):488-94.

28. Tien PC, Kotler DP, Overton ET, Lewis CE, Rimland D, Bacchetti P, Scherzer R, **Gripshover B**; for the Study of Fat Redistribution and Metabolic Change in HIV Infection Investigators. Regional Adipose Tissue and Elevations in Serum Aminotransferases in HIV-Infected Individuals. *J Acquir Immune Defic Syndr*. 2008 Jun 1; 48 (2):169-76.

29. Hileman CO, Carman TL, **Gripshover BM**, O'Riordan M, Storer NJ, Harrill DE, White CA, McComsey GA. Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. *AIDS*. 2010 Jul 31;24(12):1958-61.

30. Jinno S, **Gripshover BM**, Lemonovich TL, Anderson JM, Jacobs MR. A case of *Histoplasma capsulatum* prosthetic valve endocarditis with negative *Histoplasma* antigen in an immunocompetent patient. *J Clin Microbiol*. 2010 Dec;48(12):4664-6.

31. Ma Q, Zingman BS, Luque AE, Fischl MA, **Gripshover BM**, Venuto CS, Difrancesco R, Forrest A, Morse GD. Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in

HIV-Infected Individuals with Active Substance-Related Disorders. *Ther Drug Monit.* 2011 Jun;33(3):309-314.

32. Mehlotra RK, Cheruvu VK, Blood Zikursh MJ, Benish RL, Lederman MM, Salata RA, **Gripshover B**, McComsey GA, Lisgaris MV, Fulton S, Subauste CS, Jurevic RJ, Guillemette C, Zimmerman PA, Rodriguez B. Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. *J Infect Dis.* 2011 Jul; 204(2):291-8.

33. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, **Gripshover B**, Salata RA, Taeye A, Lisgaris M, McComsey GA, Kirchner E, Baum J, Shive C, Asaad R, Kalayjian RC, Sieg SF, Rodriguez B. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. *J Infect Dis.* 2011 Oct 15; 204(8):1217-26.

34. Slomka J, Lim JW, **Gripshover B**, Daly B. How Have Long-Term Survivors Coped with Living With HIV? *J Assoc Nurses AIDS Care.* 2013 Sep-Oct;24(5):449-59. PMID: 23253776

35. Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, **Gripshover B**, Bosch RJ. CD8+ T-Cell Activation in HIV-1-Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy. *J Acquir Immune Defic Syndr.* 2013 May 1;63(1):101-104. PMID: 23392463

36. Mittelsteadt AL, Hileman CO, Harris SR, Payne KM, **Gripshover BM**, McComsey GA. Effects of HIV and Antiretroviral Therapy on Resting Energy Expenditure in Adult HIV-Infected Women-A Matched, Prospective, Cross-Sectional Study. *J Acad Nutr Diet.* 2013 Apr 10.(13)176-7. PMID: 23601434

37. Webel AR, Longenecker CT, **Gripshover B**, Hanson JE, Schmotzer BJ, Salata RA. Age, stress, and isolation in older adults living with HIV. *AIDS Care.* 2014 26(5):523-31. [Epub 2013 Oct 13] PMID: 24116852

38. Webel AR, Barkley J, Longenecker CT, Mittelsteadt A, **Gripshover B**, Salata RA. A Cross-Sectional Description of Age and Gender Differences in Exercise Patterns in Adults Living With HIV. *J Assoc Nurses AIDS Care.* 2015 Mar-Apr 26(2):176-86. doi: 10.1016/j.jana.2014.06.004. [Epub 2014 Jul 5] PMID:25249267

39. Bednasz C, Luque AE, Zingman BS, Fischl MA, **Gripshover BM**, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q. Lipid-lowering therapy in HIV-infected patients: relationship with antiretroviral agents and impact of substance-related disorders. *Curr Vasc Pharmacol.* 2016 Jan 6 [Epub ahead of print] PMID: 26733388

Peer Reviewed Publications as Collaborator (part of clinical trial team, cited in acknowledgements and included in PubMed)

1. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, Punyanitya M, Heymsfield SB, Grunfeld C; Study of Fat Redistribution Metabolic Change in HIV Infection. Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. *Am J Clin Nutr*. 2008 Oct;88(4):1088-96.
2. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med*. 2008 Oct 2;359(14):1442-55.
3. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. *N Engl J Med*. 2008 Oct 2;359(14):1429-41.
4. Hulgán T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Moutsings AA, Kallianpur AR; AIDS Clinical Trials Group 384 and A5005s Study Teams. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipodystrophy during antiretroviral therapy. *J Infect Dis*. 2008 Mar 15;197(6):858-66. Erratum in: *J Infect Dis*. 2008 Jun 1;197(11):1630.
5. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfeld C; FRAM Study Investigators. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. *J Acquir Immune Defic Syndr*. 2008 May 1;48(1):44-52.
6. Currier J, Scherzer R, Bacchetti P, Heymsfield S, Lee D, Sidney S, Tien PC; Fat Redistribution and Metabolic Changes in HIV Infection Study Investigators. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. *J Acquir Immune Defic Syndr*. 2008 May 1;48(1):35-43.
7. Grunfeld C, Delaney J, Wanke C, Currier J, Scherzer R, Biggs ML, Tien P, Shlipak M, Sidney S, Polak J, O'Leary D, Bacchetti P, Kronmal R, for the study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. *AIDS*. 2009 Sep 10;23(14):1841-9.
8. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med* 2009 Dec 3;361(23):2230-40.
9. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, Grunfeld C, Shlipak M, Tien PC. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. *J Acquir Immune Defic Syndr*. 2010 Jan 1;53(1):102-6.
10. Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, Tien PC, Bacchetti P, Shlipak M, Scherzer R; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. *AIDS*. 2010 Jul 17;24(11):1717-26.

11. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B; AIDS Clinical Trials Group 5197 Study Team. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. *J Infect Dis*. 2010 Sep 1;202(5):705-16.
12. Hammer SM, Ribaud H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. *HIV Clin Trials*. 2010 Nov-Dec;11(6):312-24.
13. Yarasheski KE, Scherzer R, Kotler DP, Dobs AS, Tien PC, Lewis CE, Kronmal RA, Heymsfield SB, Bacchetti P, Grunfeld C; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. *J Gerontol A Biol Sci Med Sci*. 2011 Mar;66(3):332-40. Epub 2011 Feb 10.
14. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC; AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. *Ann Intern Med*. 2011 Apr 5;154(7):445-56. Epub 2011 Feb 14.
15. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, Shlipak MG, Grunfeld C; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. *AIDS*. 2011 Jul 17;25(11):1405-14.
16. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *J Infect Dis*. 2011 Oct 15;204(8):1191-201.
17. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. *Clin Infect Dis*. 2014 Feb;58(4):555-63.

Book Chapters

1. **Gripshover BM** and Ellner JJ: Chronic Meningitis in Mandell GL, Douglas RG, and Bennett JE (eds), *Principles and Practice of Infectious Diseases*. Churchill Livingstone, New York, 4th ed, 1995, pp. 865-874.

2. **Gripshover BM** and Ellner: The chronic meningitis syndrome and meningitis of non-infective or uncertain etiology in Scheld WM, Whitley RJ, and Durack DT (eds), *Infections of the Central Nervous System*. Lippincott-Raven, Philadelphia. 1997, pp. 881-896.
3. **Gripshover BM** and Aron DC: Status of endocrine disease with HIV infection in Bardin CW (ed), *Current Therapy in Endocrinology and Metabolism*. Mosby-Year Book, Philadelphia, 1997, pp. 210-215.
4. **Gripshover BM** and Ellner JJ. Chronic Meningitis in Mandell GL, Douglas RG, and Bennett JE (eds), *Principles and Practices in Infectious Diseases 5th edition*. Churchill Livingstone, New York, 2000, pp.997-1009
5. **Gripshover BM** and Valdez H: Common Sexually Transmitted Diseases in Tan, J S (ed), *Expert Guide to Infectious Diseases*. American College of Physicians, Philadelphia 2002, pp. 271-302.
6. Blossom D and **Gripshover B**: Sexually Transmitted Infections and HIV-STI Interactions, in Salata RA and Armitage KB (eds) *The Year in Infection, Volume 3*. Clinical Publishing, Oxford 2006, pp. 109-131.
7. Beigi RH and **Gripshover BM**: Common Sexually Transmitted Diseases in Tan JS, File TM, Salata RA, and Tan MJ (eds) *Expert Guide to Infectious Diseases*. American College of Physicians, Philadelphia, 2008, pp. 284-312.

Recent Selected Abstracts

1. Kucia M and **Gripshover B**. Using a clinic electronic database and multidisciplinary care team to facilitate retention in care and HIV RNA suppression. Ryan White All Titles Conference Washington DC 8/ 2012
2. Colburn N, **Gripshover B** and Avery A. Measurement of the HIV Cascade of Care using Surveillance Data in Cuyahoga County 8th International Conference on HIV Treatment Prevention Adherence Miami 6/ 2013
3. Kucia M and **Gripshover B**. Out of care by medical visits does not mean out of virologic suppression: a look at churners. #7019 Ryan White All Parts Conference Washington DC 8/2016.

Other HIV Community Advocacy

“Ohio should get rid of harmful HIV law” The Vindicator letter to the editor 9/17/17

<http://www.vindy.com/news/2017/sep/17/ysu-faculty-pondering-strike-disrespect-/?newswatch&mobile>

“A prescription for healthcare that will not make Ohioans sick” Cleveland.com Op Ed 7/5/17
http://www.cleveland.com/opinion/index.ssf/2017/07/a_prescription_for_health_care.html

Ohio HIV Criminalization reform 2016-present: working with coalition of advocates to change antiquated discriminatory HIV disclosure laws, met with state Sen Williams and Eckland

Led coalition of statewide HIV providers to send public comments opposing implementation of healthcare spending accounts on Medicaid 5/16 and another opposing Medicaid work requirements 3/18

Meet annually with congressional health policy staff for Sen. Brown, Sen Portman, and House representatives Fudge, Joyce, Kaptur, Ryan to advocate for Ryan White funding and healthcare access

“Talkbacks” following HIV-themed theatre productions: “The Normal Heart” Ensemble Theatre 10/12 and “Mothers and Sons” Beck Theatre for the Arts 11/15

HIV Outreach with our SIU team at community events including health fairs, health walks; also with UHCMC Diversity outreach